Cross talk between brain innate immunity and serotonin signaling underlies depressive-like behavior induced by Alzheimer’s amyloid-β oligomers in mice

Journal of Neuroscience

Volumn 36, Issue 48, 2016, Pages 12106-12116

  Ledo, Jose Henrique ^a   Azevedo, Estefania P ^a   Beckman, Danielle ^a   Ribeiro, Felipe C ^a   Santos, Luis E ^a   Razolli, Daniela S ^b   Kincheski, Grasielle C ^a   Melo, Helen M ^a   Bellio, Maria ^a   Teixeira, Antonio L ^c   Velloso, Licio A ^b   Foguel, Debora ^a   De Felice, Fernanda G ^a,d   Ferreira, Sergio T ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Alzheimer s; Depression; Inflammation; Microglia; Serotonin

Indexed keywords

MINOCYCLINE; SEROTONIN; TRYPTOPHAN HYDROXYLASE; AMYLOID BETA PROTEIN; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; GENE AMPLIFICATION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SUCROSE PREFERENCE TEST; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C3H MOUSE; IMMUNOLOGY; MICROGLIA; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DEPRESSION; IMMUNITY, INNATE; MALE; MICE; MICE, INBRED C3H; MICROGLIA; RECEPTOR CROSS-TALK; SEROTONIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006049436     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1269-16.2016     Document Type: Article

References (65)

1. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894-902.
2. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
3. Azevedo EP, Ledo JH, Barbosa G, Sobrinho M, Diniz L, Fonseca AC, Gomes F, Romão L, Lima FR, Palhano FL, Ferreira ST, Foguel D (2013) Activated microglia mediate synapse loss and short-term memory deficits in a mouse model of transthyretin-related oculoleptomeningeal amyloidosis. Cell Death Dis 4:e789.
4. Benilova I, De Strooper B (2013) Promiscuous Alzheimer’s amyloid: yet another partner. Science 341:1354-1355.
5. Bie B, Wu J, Yang H, Xu JJ, Brown DL, Naguib M (2014) Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency. Nat Neurosci 17:223-231.
6. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease: associated A ÷ oligomers. J Clin Invest 122:1339-1353.
7. Bonaccorso S, Lin A, Song C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Vandewoude M, Dossche A, Maes M (1998) Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT. Aging (Milano) 10:316-323.
8. Caramelli P, Barbosa MT, Sakurai E, Santos Dos EL, Beato RG, Machado JC, Guimarães HC, Teixeira AL, Pietà Study Group (2011) The Pietà study: epidemiological investigation on successful brain aging in Caeté (MG), Brazil. Methods and baseline cohort characteristics. Arq Neuropsiquiatr 69:579-584.
9. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D’Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI (2011) Serotonin signaling is associated with lower amyloid-÷ levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 108:14968-14973.
10. Czirr E, Wyss-Coray T (2012) The immunology of neurodegeneration. J Clin Invest 122:1156-1163.
11. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46-56.
12. Ferreira ST, Klein WL (2011) The A÷ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol Learn Mem 96: 529-543.
13. Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM, Mota-Sales AP, Saraiva LM, Klein WL, Sebollela A, De Felice FG, Ferreira ST (2013) Memantine rescues transient cognitive impairment caused by high-molecular-weight a÷ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci 33:9626-9634.
14. Filali M, Lalonde R, Rivest S (2009) Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer’s disease. Genes Brain Behav 8:143-148.
15. Forny-Germano L, Lyra e Silva NM, Batista AF, Brito-Moreira J, Gralle M, Boehnke SE, Coe BC, Lablans A, Marques SA, Martinez AM, Klein WL, Houzel JC, Ferreira ST, Munoz DP, De Felice FG (2014) Alzheimer’s disease-like pathology induced by amyloid-÷ oligomers in nonhuman primates. J Neurosci 34:13629-13643.
16. Frye CA, Walf AA (2009) Progesterone reduces depression-like behavior in a murine model of Alzheimer’s disease. Age 31:143-153.
17. Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM (2008) History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70:1258-1264.
18. Geldenhuys WJ, Van der Schyf CJ (2011) Role of serotonin in Alzheimer’s disease: a new therapeutic target? CNS Drugs 25:765-781.
19. Grassi-Oliveira R, Brietzke E, Pezzi JC, Lopes RP, Teixeira AL, Bauer ME (2009) Increased soluble tumor necrosis factor-receptors in patients with major depressive disorder. Psychiatry and Clinical Neurosciences 63:202-208.
20. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L (2003) Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol 60:753-759.
21. Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14:463-477.
22. Heneka MT, Golenbock DT, Latz E (2015) Innate immunity in Alzheimer’s disease. Nat Immunol 16:229-236.
23. Kang HJ, Voleti B, Hajszan T, Rajkowska G, Stockmeier CA, Licznerski P, Lepack A, Majik MS, Jeong LS, Banasr M, Son H, Duman RS (2012) Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 18:1413-1417.
24. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME (2006) Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc Natl Acad Sci U S A 103:702-707.
25. Kobayashi K, Imagama S, Ohgomori T, Hirano K, Uchimura K, Sakamoto K, Hirakawa A, Takeuchi H, Suzumura A, Ishiguro N, Kadomatsu K (2013) Minocycline selectively inhibits M1 polarization of microglia. Cell Death Dis 4:e525.
26. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453.
27. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100:23-35.
28. Ledo JH, Azevedo EP, Clarke JR, Ribeiro FC, Figueiredo CP, Foguel D, De Felice FG, Ferreira ST (2013) Amyloid-÷ oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry 18:1053-1054.
29. Lezoualc’h F (2007) 5-HT4 receptor and Alzheimer’s disease: the amyloid connection. Exp Neurol 205:325-329.
30. Lorke DE, Lu G, Cho E, Yew DT (2006) Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci 7:36.
31. Lourenco MV et al. (2013) TNF-mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s ÷-amyloid oligomers in mice and monkeys. Cell Metab 18:831-843.
32. Lyketsos CG, Olin J (2002) Depression in Alzheimer’s disease: overview and treatment. Biol Psychiatry 52:243-252.
33. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid ÷-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2:a006338.
34. Nau F Jr, Yu B, Martin D, Nichols CD (2013) Serotonin 5-HT2A receptor activation blocks TNF-mediated inflammation in vivo. PLoS One 8:e75426.
35. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13-25.
36. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV (2009) Toll-like receptors in neurodegeneration. Brain Res Rev 59:278-292.
37. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63:530-538.
38. Park KM, Bowers WJ (2010) Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 22:977-983.
39. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/ 10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
40. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732.
41. Rodríguez JJ, Noristani HN, Verkhratsky A (2012) The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol 99:15-41.
42. Romano A, Pace L, Tempesta B, Lavecchia AM, Macheda T, Bedse G, Petrella A, Cifani C, Serviddio G, Vendemiale G, Gaetani S, Cassano T (2014) Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer’s disease. Int J Neuropsychopharmacol 18: pii: pyu020.
43. Sachs BD, Ni JR, Caron MG (2015) Brain 5-HT deficiency increases stress vulnerability and impairs antidepressant responses following psychosocial stress. Proc Natl Acad Sci U S A 112:2557-2562.
44. Santos LE, Beckman D, Ferreira ST (2016) Microglial dysfunction connects depression and Alzheimer’s disease. Brain Behav Immun 55:151-165.
45. Schmidt HD, Duman RS (2007) The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18:391-418.
46. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108.
47. Selkoe DJ (2011) Alzheimer’s disease. Cold Spring Harb Perspect Biol 3:a004457.
48. Starkstein SE, Mizrahi R (2006) Depression in Alzheimer’s disease. Expert Rev Neurother 6:887-895.
49. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P (2006) Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311:77-80.
50. Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P (2013) p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci 14:673-680.
51. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 68:930-941.
52. Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, Siler DA, Markesbery WR, Arumugam TV, Mattson MP (2008) Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp Neurol 213:114-121.
53. Trotta T, Porro C, Calvello R, Panaro MA (2014) Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol 268:1-12.
54. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E (2003) Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 170:429-433.
55. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R (2006) Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29-35.
56. van Rooijen N, Hendrikx E (2010) Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 605:189-203.
57. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 20:947-956.
58. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P (2011) Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 108:9262-9267.
59. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M (2005) IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10: 538-544.
60. Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D (2003) Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 10:1581-1591.
61. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35:419-432.
62. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2:a006346.
63. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (2008) Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 327:316-323.
64. Zarros AC, Kalopita KS, Tsakiris ST (2005) Serotoninergic impairment and aggressive behavior in Alzheimer’s disease. Acta Neurobiol Exp (Wars) 65:277-286.
65. Zhu CB, Blakely RD, Hewlett WA (2006) The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31:2121-2131.